About US
Contact us
-
Japan poised to put 70% price lid on biosimilars, cap generics at 50% of reference drugJapanis considering capping the price of biosimilars at 70% of the reference drug, while lowering the price cap on generics from 60% to 50% of the price for the drugs they copy. The government has pus2015/12/4
-
Can Pfizer finally orchestrate a winning megamerger after so many disappointments?Pfizer's ($PFE) decision to buy Allergan ($AGN) wasn't much of a surprise; the nominally Dublin-based Allergan was among the few buyout targets that could deliver CEOIan Read's desired tax inversion.2015/12/3
-
Novo touts SGLT2-topping data for blockbuster VictozaSGLT2 drugs may be in the diabetes spotlight thanks to recent data showing that one of them--Eli Lilly ($LLY) andBoehringer Ingelheim'sJardiance--could cut cardiovascular risks. But Novo Nordisk ($NVO2015/12/3
-
Sanofi's Praluent scores first place in line for UnitedHealth unit's PCSK9 patientsHere's one way to privilege a new drug over its rival without blocking one entirely: Make patients try your favored product first. That's what UnitedHealth's ($UNH) Oxford unit is doing with the two2015/12/2
-
Russia amps up spending on locally made meds to spur Big Pharma productionRussiahas a lot of purchasing muscle, but few local producers when it comes to pharmaceuticals, and so officials have cooked up a plan to lure more foreign pharma partners. The government will boost i2015/12/2
-
Sanofi execs working with Lazard on $12B animal health sale or spinoffJust a couple of weeks ago, Sanofi ($SNY) announced that it was mulling options for its animal health unit,Merial, which offered "limited synergies" with the rest of the company. Now, investment banke2015/12/1
-
Samsung ponies up $740M to create massive biologics production site in South KoreaSamsung BioLogics, which is partnered up on biologics projects with a who's who of Western drugmakers, moved its biosimilars effort forward significantly this month with an EU recommendation for a cop2015/12/1
-
Xellia Pharma buys former Boehringer Ben Venue plant, once the poster child of quality failingsDenmark's Xellia Pharmaceuticals has bought the formerBen Venueplant, at one time the most notorious U.S. plant underFDAsupervision, and the facility responsible for dozens of recalls and a slew of dr2015/11/30
-
Turing offers discounts instead of cutting controversial list price on DaraprimTuring Pharmaceuticalshas been saying for a while now that it would lower the price of its toxoplasmosis med, Daraprim, responding to growing backlash from lawmakers and the public after it bought the2015/11/30
-
Mylan may soon find itself wrestling former target Perrigo for dealsEarlier this month, Perrigo ($PRGO) shareholders spurned a hostile buyout attempt from Mylan ($MYL). And now, the Netherlands-based company may have to go up against its former target if it wants to p2015/11/27